Overview: Wells Fargo recently maintained its neutral “Equal-Weight” stance on The Clorox Company (NYSE: CLX) but cut its price target from $130 to $125 ([1]). Analyst Chris Carey cited weak consumer consumption data and potential growth challenges as key reasons for the downward revision ([2]). This follows a series of target reductions by multiple analysts in 2025 amid cautious industry outlooks ([2]). Clorox’s stock has already fallen sharply from its pandemic highs – it is down ~39% from its all-time peak in August 2020 ([3]) – leaving investors wondering what comes next for the company. Below, we delve into Clorox’s dividend profile, leverage and debt maturities, valuation, and the risks/red flags that could shape its trajectory going forward.
Dividend Policy and History
Congratulations — Your seat is almost reserved!
Get 6 ten-bagger ideas + alerts from Gerardo. Instant access when you join.
Clorox is a storied dividend payer with 47 consecutive years of annual dividend increases ([4]), solidifying its status as a Dividend Aristocrat. Even through economic cycles, the company has prioritized maintaining and growing its payout, reflecting the resilient cash flows of its household staples business. As of early 2026 Clorox’s indicated annual dividend is $4.96 per share, which at the recent share price yields approximately 4.8% ([5]). This yield is near multi-year highs and well above that of many consumer-staples peers, signaling both an attractive income stream and the market’s tempered growth expectations for Clorox. Management enacted a modest 2% dividend hike in mid-2024 ([6]) ([6]), consistent with the slow but steady increases of recent years.
Despite its strong dividend heritage, investors are examining the sustainability of Clorox’s payout in light of recent earnings volatility. Historically, Clorox’s dividend was comfortably covered – between fiscal 2018 and 2021 it paid out an average of ~63% of net income and ~56% of free cash flow as dividends ([3]), leaving ample cushion for reinvestment. In fiscal 2023, for example, free cash flow was about $930 million (12.6% of net sales) against ~$583 million in dividends paid ([6]) ([6]), a healthy coverage ratio. However, the picture changed in fiscal 2024: free cash flow dropped to $483 million (6.8% of sales) ([6]) due to working-capital swings and one-time costs, while dividends totaled $595 million ([6]). In other words, the dividend outstripped free cash generation in the most recent year. This gap appears temporary – driven by a large inventory rebuild and tax payments – but it underscores that Clorox has become more reliant on its balance sheet to fund shareholder returns in the short term. The company still managed to cover its payout from cash on hand and short-term borrowing, and management remains committed to the dividend. Going forward, investors will be watching for a rebound in earnings and cash flow (excluding one-offs) to bring the payout ratio back to more sustainable levels. Clorox’s long record suggests a cut is unlikely barring extreme circumstances ([3]), but minimal dividend growth (or a pause in raises) is possible if profit recovery stalls.
Leverage, Debt Maturities, and Coverage
Clorox’s leverage profile is somewhat elevated for a consumer staples company, in part due to accounting effects on equity. As of June 30, 2024, the company carried $2.48 billion in long-term debt ([6]) and only about $328 million in shareholders’ equity ([6]) (excluding non-controlling interests). Years of share buybacks and a hefty goodwill write-down have eroded the book equity, resulting in an unusually high debt-to-equity ratio. In fact, Clorox’s debt-to-equity stands above 13× ([2]) – a figure that may raise eyebrows. It’s important to note this is a balance-sheet artifact (the company’s market capitalization far exceeds book equity), but it does signal that Clorox has less balance-sheet buffer than peers should more debt be needed. Debt to EBITDA is a more relevant metric; by that measure leverage is moderate (roughly 2× EBITDA based on recent results), consistent with an investment-grade credit profile. Both S&P and Moody’s rate Clorox in the BBB+/Baa1 range (stable outlook), reflecting its steady cash flows and manageable debt load.
Encouragingly, Clorox faces no significant debt maturities in the near term. According to the latest filings, no long-term debt comes due until fiscal 2028 ([6]). The company has a well-laddered maturity schedule: about $900 million is due in FY2028, $500 million in FY2029, and roughly $1.1 billion thereafter ([6]). In the interim (FY2025–2027) Clorox can focus on reinvestment and debt paydown at its discretion without major refinancing pressures. The weighted-average interest rate on its senior notes is relatively low – about 3.25% as of mid-2024 ([6]) – which helps keep interest expense in check. Annual interest expense was approximately $90 million in FY2024 ([6]), flat versus the prior year as debt levels held steady. With fiscal 2024 earnings before taxes around $398 million ([6]) (significantly depressed by one-time charges), Clorox’s EBIT covered interest roughly 4–5×, and coverage would be higher when excluding unusual costs. This suggests the company can comfortably service its debt under normal conditions.
Liquidity appears adequate but not robust. Clorox had minimal short-term borrowings ($4 million of notes payable) on its balance sheet at FY2024 year-end ([6]), and it maintains committed credit facilities to support commercial paper issuance for working capital. The current ratio is only ~0.74 ([2]), partly because Clorox relies on efficient cash conversion cycles (e.g. turning over inventory quickly and using trade payables). While a sub-1 current ratio isn’t unusual for a stable consumer products firm, it means Clorox depends on continued access to short-term credit markets for flexibility. Fortunately, its strong credit ratings and cash flow generation provide that access. A potential use of cash on the horizon is Clorox’s plan to buy out the remaining 20% stake in its Glad® trash-bag joint venture from Procter & Gamble in January 2026 ([4]). This transaction will require a cash payment (amount undisclosed) to P&G. Clorox will likely fund it with a mix of internal cash and commercial paper or bonds. Investors should monitor how this Glad stake acquisition impacts leverage – it could temporarily bump up debt, though owning 100% of Glad should boost future cash flows (no more dividends to P&G). Overall, Clorox’s debt is manageable and well-structured, but there is little room for complacency. The company’s low equity base and recent cash flow shortfall make prudent balance-sheet management a priority, especially if any new headwinds emerge.
Valuation and Comparative Metrics
After the recent sell-off, Clorox’s valuation has reset to a more modest level compared to its pandemic peak. The stock now trades around 15–16× earnings (price-to-earnings ratio) based on the latest figures ([7]). As of January 2026, Clorox’s trailing P/E was about 15.5 ([7]), down from roughly 19× just a few months earlier in late 2025 ([7]). This compression reflects both a decline in the stock price and a recovery in earnings from the anomaly of 2023–2024 (when one-off charges made the P/E temporarily sky-high). For context, Clorox’s P/E hovered in the high teens to ~20 range for much of the late 2010s ([7]) when the company was growing modestly and enjoying stable margins. During the early COVID boom (mid-2020), the market briefly valued Clorox over 25× earnings ([7]) as sales and profits surged with heightened demand for cleaning products. That premium has long since evaporated.
On a forward-looking basis, Clorox management has guided to fiscal 2025 GAAP earnings of roughly $5.07 per share at the midpoint ([8]) ([8]) (and about $6.65 on an adjusted basis excluding one-time charges ([8])). At the current stock price, this implies a forward P/E in the low-20s on GAAP earnings or around ~16× on adjusted earnings – indicating the market is pricing in very little growth. By comparison, mega-cap peer Procter & Gamble trades near 20× earnings ([9]) and offers a 2.5% dividend yield, while Kimberly-Clark is about 18× earnings with a ~3.7% yield. Clorox’s 4.5–5% dividend yield and ~16× normalized P/E suggest it is valued at a discount to higher-growth or larger staples peers, and roughly in line with its own slower growth outlook. In other words, the stock’s valuation now embeds a healthy degree of skepticism. This could set the stage for upside if Clorox outperforms expectations – or further downside if the turnaround disappoints. It’s worth noting Clorox’s EV/EBITDA (enterprise value to EBITDA) is around the mid-12× range currently, which is reasonable for a stable cash-generative business, though not a blatant bargain.
From a yield perspective, Clorox’s nearly 5% yield is one of the richest among consumer defensive stocks. Such a high yield in this sector can be a double-edged sword: it provides strong income to shareholders, but it also signals that the market has concerns (investors demand a higher yield as compensation for perceived risk). If Clorox can stabilize its earnings and resume modest growth, the current valuation could be seen as attractive – essentially offering a bond-like yield plus any upside from operational improvements. However, if earnings were to deteriorate further or if the dividend’s safety came into question, the stock could languish or fall until a new equilibrium yield is reached. At present, the valuation appears fair relative to Clorox’s near-term prospects, with the market in “wait and see” mode. Any clear signs of renewed growth or margin expansion would likely lead to multiple expansion (and stock upside), whereas negative surprises could lead to the stock testing deeper value territory.
Risks and Red Flags
Clorox faces a mix of industry-wide headwinds and company-specific risks that investors should keep in mind. Soft consumer demand and high price sensitivity are a prominent concern: the company has flagged weakened U.S. consumer sentiment and retail destocking as factors weighing on sales ([2]). With inflationary pressures, shoppers have been more inclined to trade down to cheaper brands or buy on promotion, which can hurt Clorox’s volumes. Indeed, competitive promotional activity in categories like cleaning and household essentials has picked up, forcing Clorox to balance pricing vs. market share ([2]). The firm managed to achieve its 10th consecutive quarter of gross margin expansion recently ([2]) – thanks to cost savings and easing commodity costs – but sustaining margin gains might require further price hikes or efficiency gains. Pushing prices higher, however, could exacerbate volume declines if consumers push back. This margin-volume tradeoff is a key risk: Clorox’s ability to grow profitably depends on navigating it delicately in an environment where buyers are more cost-conscious.
Another red flag is the one-time setbacks and their lingering impact. In August 2023, Clorox suffered a major cybersecurity breach that disrupted its operations ([10]). The attack shut down systems, causing order processing delays and significant product outages that negatively hit sales and earnings ([10]). The company incurred an estimated $49 million in direct costs from the incident ([10]), and perhaps even more in lost revenue opportunity during the recovery. While Clorox has largely resolved those issues (with insurance recoveries offsetting some costs), the episode highlighted vulnerabilities in its infrastructure. Operational risks – whether from cyber events, supply chain disruptions, or natural disasters – remain on the radar. Any similar disruption can have outsized effects on a lean supply chain. Clorox’s response was to accelerate investments in IT and digital capabilities (it is spending ~$90–100 million on a digital transformation initiative in FY2025) ([8]) ([8]), which should improve resilience but also adds expense in the near term.
Clorox’s financial flexibility is not as great as it once was. The company’s balance sheet carries little slack – as noted earlier, shareholder equity is very low and the debt load, while manageable, is substantial. A consequence is that Clorox has limited room for large acquisitions or aggressive buybacks until earnings grow again. The company already took a big goodwill impairment charge of $445 million in 2023 related to its vitamins, minerals, and supplements (VMS) business ([8]), acknowledging that past diversification into that area didn’t pan out. It has since agreed to divest the VMS unit entirely ([8]). Writing off that goodwill and exiting a non-core business was a prudent move, but it also underscores the risk of strategy missteps. Clorox must now focus on its core brands – cleaning products, household goods, and lifestyle brands like Brita and Burt’s Bees – for growth. Any mis-execution in brand management or product innovation here would be a risk to its recovery. The competitive landscape includes not only traditional rivals (like Colgate-Palmolive, Reckitt, or private labels) but also emerging trends (e.g. eco-friendly cleaners, direct-to-consumer upstarts) that could threaten legacy brands if Clorox doesn’t keep up with consumer preferences.
Additional risks include macroeconomic and regulatory factors. Clorox generates over 80% of sales in the U.S. ([1]), so its fortunes are tied to American consumer health. A U.S. recession or further erosion in consumer confidence could dent demand for discretionary products (e.g. Brita filters or Burt’s Bees skincare) even if bleach and trash bags remain staples. Inflation in labor or raw materials, if it re-accelerates, could pressure margins again – Clorox benefited from lower commodity costs recently ([8]), but that could reverse. Tariffs or trade barriers (particularly given Clorox’s global supply inputs and international sales) pose another risk ([2]). Furthermore, environmental, social, and governance (ESG) issues are increasingly salient: for example, Clorox uses chlorine in bleach production, which brings regulatory scrutiny and environmental liability concerns ([8]). The company must also continue to uphold its strong safety and quality reputation; any significant product recall or safety incident (in cleaning chemicals or food products like Hidden Valley) would be a serious setback. Lastly, the stock’s high dividend yield itself can be seen as a market signal of risk – if Clorox underperforms and cash flows disappoint, the company could be forced to slow dividend growth or, in a worst case, consider a cut (breaking its 47-year streak). While such a move seems a remote possibility today, it remains a risk factor that income-focused investors cannot ignore.
Outlook and Open Questions
With Wells Fargo’s caution in mind and Clorox navigating a challenging environment, what lies ahead for the company? Management is guiding for flat to slightly down net sales in FY2025 (0% to –2% year-over-year) as underlying organic growth of +3% to +5% is offset by the sale of the Argentina and VMS businesses ([8]). They also forecast a return to mid-single-digit adjusted EPS growth in FY2025 ([8]) ([8]), thanks to cost savings and the lapping of one-time losses. These targets set the stage, but several open questions remain:
– Can Clorox re-ignite volume growth? Recent sales trends have relied heavily on pricing, while volumes in some categories declined amid weak consumption. A key question is whether unit volumes will stabilize or grow in core segments (cleaning, household, lifestyle) as the company laps tough comparisons and consumers adjust to new price levels. If consumers continue to down-trade or if private-label offerings gain share, Clorox could struggle to lift sales even with new products.
– Will margin expansion persist? Clorox has impressively delivered multiple quarters of gross margin improvement ([2]) by cutting costs and benefiting from lower commodity prices. However, cost pressures (wages, materials) are an ever-present risk. It remains to be seen if the company can keep expanding margins – or even hold them – if inflationary trends flare up or if it must increase promotions to spur volume. The outcome will directly impact its earnings leverage going forward.
– How will the balance sheet evolve post-Glad acquisition? The upcoming buyout of P&G’s stake in the Glad business will give Clorox full ownership of a profitable franchise, but it could also bump up debt or temporarily strain cash reserves. Investors will watch for details on the purchase price and financing. Successfully integrating the remaining Glad operations and capturing 100% of its cash flow (versus 80% previously) could help de-lever over time – but if more debt is taken on, Clorox’s leverage ratios and credit ratings might face pressure. This raises the question: will Clorox prioritize debt reduction with any excess cash, or resume share buybacks once Glad is fully owned? The answer will signal management’s financial strategy in a rising-rate world.
– Is the dividend sacrosanct? Clorox’s management has expressed strong commitment to the dividend, but with the payout ratio elevated recently, some wonder if dividend growth might slow until earnings catch up. The company’s 2% hike last year was modest ([6]); will similar token raises continue to preserve the Aristocrat streak? Conversely, if performance improves, could Clorox accelerate dividend growth again? The trajectory of free cash flow in the next few quarters will be telling. Thus far there are no red flags around dividend safety, but this will remain an important watch item for shareholder returns.
– What is the longer-term growth plan? Clorox’s core business is mature, and the pandemic pulled forward some demand (with sanitizing products seeing a spike then normalization). Management’s IGNITE strategy focuses on innovation, digital transformation, and cost efficiency ([8]). The open question is whether these initiatives can deliver a meaningful growth runway. Are there adjacent categories Clorox can expand into (organically or via bolt-on acquisitions) to move the needle? Will the company lean more on international markets (currently ~20% of sales) for growth, or double down in the U.S. with new products? Thus far, Clorox has been pruning non-core businesses (like VMS) to focus on what it does best – but investors may look for signs of a bolder strategy to drive growth above low-single-digits. Any commentary on M&A plans, new product pipelines, or e-commerce/channel expansion could shape the market’s view of Clorox’s long-term prospects.
Conclusion: Clorox finds itself at an inflection point. Wells Fargo’s lowered price target reflects near-term caution amid consumption headwinds, yet the company’s fundamentals – a portfolio of strong brands, decades of dividend consistency, and solid cash flow – provide a foundation for stability. The stock’s pullback has made its valuation and yield compelling for value-oriented investors, if Clorox can navigate the current challenges. In the coming quarters, all eyes will be on execution: restoring sales momentum (organically, without one-off disruptions), sustaining margins while investing in the business, and deleveraging after strategic moves like the Glad acquisition. Management’s ability to address the open questions above will determine whether Clorox can regain market confidence. For now, the consensus on Wall Street is neutral ([1]) – a “wait-and-see” hold pattern. As we await the next earnings reports and updates, Clorox’s progress on its turnaround and the resilience of its dividend will be key factors in charting the stock’s path forward. Investors should remain vigilant about the risks but also recognize that a stabilizing consumer backdrop or operational win (beyond what analysts expect) could quickly shift the narrative for this household-name company. Clorox has weathered many periods of adversity in its century-long history; how it responds to today’s tests will inform what’s next for CLX.
Sources:
1. GuruFocus News – Wells Fargo Lowers Price Target for Clorox to $125 (Sep 25, 2025) ([1]) ([1]) 2. Ainvest – Clorox Price Target Cut Amid Consumption Concerns; Wells Fargo Adjusts Estimate (Jul 12, 2025) ([2]) ([2]) 3. Sure Dividend – Dividend Aristocrats in Focus: Clorox (Feb 4, 2025) ([4]) ([4]) 4. MacroTrends – Clorox Dividend History and Yield ([5]); Clorox P/E Ratio & Historical Data ([7]) ([7]) 5. SEC Filing – Clorox FY2024 Annual Report (Form 10-K, Aug 2024) ([6]) ([6]) 6. SEC Filing – Clorox FY2025 Outlook, Press Release Aug 1, 2024 ([8]) ([8]) 7. Motley Fool – Is This Dividend Aristocrat’s 3.3% Yield in Jeopardy? (Feb 8, 2022) ([3]) ([3]) 8. CFO Dive – Clorox says it incurred $49M in costs from 2023 cyberattack ([10]) (impact on operations)
Sources
- https://gurufocus.com/news/3120699/wells-fargo-lowers-price-target-for-clorox-clx-to-125-clx-stock-news
- https://ainvest.com/news/clorox-price-target-cut-consumption-concerns-wells-fargo-adjusts-estimate-2507/
- https://fool.com/investing/2022/02/08/is-this-dividend-aristocrats-33-dividend-yield-in/
- https://suredividend.com/dividend-aristocrats-clx/
- https://macrotrends.net/stocks/charts/CLX/clorox/dividend-yield-history
- https://sec.gov/Archives/edgar/data/21076/000002107624000030/clx-20240630_d2.htm
- https://macrotrends.net/stocks/charts/CLX/clorox/pe-ratio
- https://investors.thecloroxcompany.com/news/news-details/2024/Clorox-Reports-Q4-and-FY24-Results-Provides-FY25-Outlook/default.aspx
- https://macrotrends.net/stocks/charts/PG/procter-gamble/pe-ratio
- https://cfodive.com/news/clorox-incurred-49million-costs-2023-cyberattack/706640/
For informational purposes only; not investment advice.